Shenzhen Kangtai Biological Products Co., Ltd.
Symbol: 300601.SZ
SHZ
22.57
CNYTrhová cena dnes
33.0556
Pomer P/E
-0.2996
Pomer PEG
24.02B
MRK Cap
- 0.01%
Výnos DIV
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4599.59 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 720.3 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 11088.33 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 3331.33 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 2231.38 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 21250.63 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 22827.08 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 3309.55 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 2537.58 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 7180.63 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 37863.92 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 2706.32 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 1082.42 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 80.82 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 8995.05 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 1296.77 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 102.52 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 3352.38 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 10251.7 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 20652.76 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 4467.66 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 8977.1 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 18507.33 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 6181.04 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 38133.13 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | -0.04 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 38133.09 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 59114.56 | - | - | - | ||||||||||||
Total Investments | 3836.89 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 10077.46 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 6198.17 | 1351 | 1271.7 | -811.4 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 709.91 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 35.58 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | -40.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 6.38 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | -411.69 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | -417.18 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 8.68 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | -3.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 318.01 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 884.06 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0.9 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | -1042 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 831.5 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | -57.67 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -909.91 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | -289.42 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | -58.07 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | -201.98 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | -237.32 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 390.66 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -64.64 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.04 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -77.03 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 3832.6 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3909.63 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 884.06 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 183.74 | -764.7 | -888.1 | -786.8 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3167.52 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 531.13 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 2636.4 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 511.11 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 84.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 1900.36 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 2431.49 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 117.17 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 185.67 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 947.68 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 675.06 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 763.66 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 53.79 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 709.91 | 861.3 | -132.7 | 1263.4 |
Často kladené otázky
Čo je Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) celkové aktíva?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) celkové aktíva sú 15085358535.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 1451440163.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.832.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je 0.165.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.224.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.213.
Aká je Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je 861303903.000.
Aký je celkový dlh firmy?
Celkový dlh je 2546554090.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 2054244031.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 876163610.000.